Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.
Fuzuloparib ± Apatinib Significantly Boosts PFS in BRCA+ HER2– Metastatic Breast Cancer
Revisit the OncLive On Air Episodes From February 2024
Ongoing Research Drives Further Questions in Early-Stage Breast Cancer Management
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
Final USPSTF Recommendation Statement Advises Women Begin Receiving Mammograms at 40 Years Old
The Road Beyond Frontline CDK4/6 Inhibitors in HR+/HER2– Metastatic Breast Cancer Examines Combinations
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC